Deliver cumulative annual revenue growth from sustainable solutions portfolio of 8-12% Assess top 90% of supplier spend for alignment with Avient Sustainability objectives. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 81% Median: 78% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of July 28, 2021 87 90 86 82 80 78 73 87 82 82 79 79 78 78 77 76 71 67 46 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E IF F A S H E C L B N R E M N H X L H U N K R A S C L A L B (6) Source: Peer data per Bloomberg market data as of July 28, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies.

This organization is a CEO-led, cross-sector, not-for- profit made up of approximately 90 companies. The Named Executive Officers are permitted to elect to defer up to 90% of their salary and annual bonus between the Qualified Savings Plan and the Supplemental Plan. Sixty days prior to the first anniversary of this date will be January 29, 2024, and 90 days prior to the first anniversary of this date will be December 30, 2023.

This organization is a CEO-led, cross-sector, not-for-profit made up of approximately 90 companies. Garratt 2/08/2021 — — — — — 5,417 225,185 2/14/2022 — — — — — 4,794 199,287 2/17/2023 — — — — — 5,701 236,991 2/04/2015 9,200 — — 38.27 2/04/2025 — — 2/15/2017 13,250 — — 34.10 2/15/2027 — — 2/14/2018 11,050 — — 41.89 2/14/2028 — — 2/11/2019 18,200 — — 31.54 2/11/2029 — — 2/10/2020 19,650 — — 31.48 2/10/2030 — — 2/08/2021 13,433 6,717 — 42.27 2/08/2031 — — 2/14/2022 — — 16,000 52.64 2/14/2032 — — 2/17/2023 — — 18,800 42.93 2/17/2033 — — J.R. The Named Executive Officers are permitted to elect to defer up to 90% of their salary and annual bonus between the Qualified Savings Plan and the Supplemental Plan.

This represents sales and adjusted EPS growth of 26% and 90%, respectively, over the prior year second quarter."

Custom Versalloy™ HC 9220-90 formulation provides regulatory compliance for drug transfer device 

美国环境保护署（EPA）指出，在过去的50年里，碳排放量增加了90%。

$90 million

We grew organic sales in each of the regions with both our Color, Additives and Inks and Specialty Engineered Materials segments growing at 3% and 6%, respectively, while expanding adjusted EBITDA margins 90 and 110 basis points, respectively, over 2023."

We focused on controlling costs and reducing working capital, generating an additional $90 million of free cash flow above our previous projections.

Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 36 79 87 83 81 76 73 90 79 77 76 73 69 60 22 A vi e n t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L M U LT I P L E E X PA N S I O N Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of April 28, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.51.